Analytical Data
-
基因名
E2IG5
- Application
-
别名
FAM162A; C3orf28; E2IG5; DC16; FWP001; Protein FAM162A; E2-induced gene 5 protein; Growth and transformation-dependent protein; HGTD-P
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q96A26
-
表达区间
1-154aa
-
氨基酸序列
MGSLSGLRLAAGSCFRLCERDVSSSLRLTRSSDLKRINGFCTKPQESPGVPSRTYNRVPLHKPTDWQKKILIWSGRFKKEDEIPETVSLEMLDAAKNKMRVKISYLMIALTVVGCIFMVIEGKKAAQRHETLTSLNLEKKARLKEEAAMKAKTE
-
分子量
42.68 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
E2IG5 is a novel recombinant protein that has garnered significant attention in biomedical research due to its potential applications in cancer therapy and immune modulation. As an isoform of the E2 ubiquitin-conjugating enzyme, E2IG5 plays a crucial role in the ubiquitin-proteasome pathway, which is essential for regulating intracellular protein degradation, cellular signaling, and homeostasis. Recent studies indicate that E2IG5 may influence tumorigenesis by modulating the stability of oncogenic and tumor suppressor proteins. Furthermore, its involvement in immune response mechanisms suggests that E2IG5 could be harnessed for therapeutic strategies aimed at enhancing anti-tumor immunity. The recombinant production of E2IG5 enables researchers to investigate its functional properties, interactions with other cellular components, and therapeutic potential in detail. Additionally, the study of E2IG5 could provide insights into the broader implications of ubiquitination processes in various disease contexts, thereby opening new avenues for the development of targeted therapies. Overall, the ongoing research on E2IG5 underscores its importance as a biomarker and a possible drug target in oncology and immunology.
